The sweet and sour of cancer: glycans as novel therapeutic targets | Nature Reviews Cancer
The pro-tumorigenic host response to cancer therapies | Nature Reviews Cancer
Are oncoantigens suitable targets for anti-tumour therapy? | Nature Reviews Cancer
Killing time for cancer cells | Nature Reviews Cancer
Cancer drug resistance: an evolving paradigm | Nature Reviews Cancer
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work | Nature Reviews Cancer
Going viral with cancer immunotherapy | Nature Reviews Cancer
The role of engineering approaches in analysing cancer invasion and metastasis | Nature Reviews Cancer
Parallel progression of primary tumours and metastases | Nature Reviews Cancer
Precision medicine for cancer with next-generation functional diagnostics | Nature Reviews Cancer
Tumorigenesis: it takes a village | Nature Reviews Cancer
Volume 4 | Nature Reviews Cancer
The metastatic niche: adapting the foreign soil | Nature Reviews Cancer
Tumour stem cells and drug resistance | Nature Reviews Cancer
Cytokines in cancer pathogenesis and cancer therapy | Nature Reviews Cancer
Improving cancer immunotherapy through nanotechnology | Nature Reviews Cancer
Next-generation computational tools for interrogating cancer immunity | Nature Reviews Genetics
The evolution of the cancer niche during multistage carcinogenesis | Nature Reviews Cancer
Is cell competition relevant to cancer? | Nature Reviews Cancer
Cancer stem cell definitions and terminology: the devil is in the details | Nature Reviews Cancer
Microenvironmental regulation of metastasis | Nature Reviews Cancer
Nature Reviews - Nature Reviews Cancer: In this Timeline... | Facebook
Volume 23 Issue 10, October 2023
Volume 23 Issue 4, April 2023
Treating metastatic cancer with nanotechnology | Nature Reviews Cancer
Nature Reviews Cancer (@NatureRevCancer) / X
Guertin Lab Review on Acetyl-CoA Metabolism in Cancer in Nature Reviews Cancer
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges | Nature Reviews Clinical Oncology
